ATE209902T1 - Neue liposomkomplexe mit erhöhter systemischer verabreichung - Google Patents

Neue liposomkomplexe mit erhöhter systemischer verabreichung

Info

Publication number
ATE209902T1
ATE209902T1 AT97938096T AT97938096T ATE209902T1 AT E209902 T1 ATE209902 T1 AT E209902T1 AT 97938096 T AT97938096 T AT 97938096T AT 97938096 T AT97938096 T AT 97938096T AT E209902 T1 ATE209902 T1 AT E209902T1
Authority
AT
Austria
Prior art keywords
liposomes
expression
highly efficient
liposome complexes
systemic administration
Prior art date
Application number
AT97938096T
Other languages
English (en)
Inventor
Nancy Smyth-Templeton
George N Pavlakis
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE209902T1 publication Critical patent/ATE209902T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AT97938096T 1996-08-19 1997-08-01 Neue liposomkomplexe mit erhöhter systemischer verabreichung ATE209902T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2438696P 1996-08-19 1996-08-19
PCT/US1997/013599 WO1998007408A1 (en) 1996-08-19 1997-08-01 Novel liposome complexes for increased systemic delivery

Publications (1)

Publication Number Publication Date
ATE209902T1 true ATE209902T1 (de) 2001-12-15

Family

ID=21820321

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97938096T ATE209902T1 (de) 1996-08-19 1997-08-01 Neue liposomkomplexe mit erhöhter systemischer verabreichung

Country Status (8)

Country Link
US (1) US6413544B1 (de)
EP (1) EP0955999B1 (de)
JP (1) JP4203835B2 (de)
AT (1) ATE209902T1 (de)
AU (1) AU730771B2 (de)
CA (1) CA2263705C (de)
DE (1) DE69708919T2 (de)
WO (1) WO1998007408A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288266B2 (en) * 1996-08-19 2007-10-30 United States Of America As Represented By The Secretary, Department Of Health And Human Services Liposome complexes for increased systemic delivery
AUPQ002399A0 (en) * 1999-04-28 1999-05-20 Australian National University, The Model membrane systems
AU5161800A (en) * 1999-05-24 2000-12-12 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
EP1754488A1 (de) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten
TR199901199A2 (xx) * 1999-05-31 2001-09-21 Kocagöz Tanil Bakteri transformasyon kiti
AUPQ259399A0 (en) 1999-09-01 1999-09-23 Lustre Investments Pte Ltd Therapeutic agents
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US6477426B1 (en) * 2000-06-20 2002-11-05 Celsion Corporation System and method for heating the prostate gland to treat and prevent the growth and spread of prostate tumors
US7037520B2 (en) 2002-03-22 2006-05-02 Baylor College Of Medicine Reversible masking of liposomal complexes for targeted delivery
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
US20060003316A1 (en) * 2002-07-15 2006-01-05 John Simard Immunogenic compositions derived from poxviruses and methods of using same
US20040048260A1 (en) * 2002-09-10 2004-03-11 Fu-Hsiung Chang Transfection of nucleic acid
EP1585504A4 (de) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Proteinstabilisierte liposomale formulierungen pharmazeutischer wirkstoffe
WO2004104032A2 (en) 2003-05-14 2004-12-02 The University Of Iowa Research Foundation Methods and compositions related to high-titer pseudotyped retroviruses
WO2005082396A2 (en) 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
WO2005092288A1 (en) 2004-03-19 2005-10-06 Let There Be Hope Medical Research Institute Carbohydrate-derivatized liposomes for targeting cellular carbohydrate recognition domains of ctl/ctld lectins, and intracellular delivery of therapeutically active compounds
AU2006339072A1 (en) 2005-03-14 2007-10-25 Board Of Regents Of The University Of Texas System Bioactive FUS1 peptides and nanoparticle-polypeptide complexes
EP1867726A4 (de) * 2005-03-24 2008-09-24 Univ Hokkaido Nat Univ Corp Zur wirksamen zuführung einer gegebenen substanz in den zellkern fähiges liposom
EP1940355B1 (de) 2005-09-30 2012-12-19 Auburn University Nanoträger zur gezielten Freisetzung eines Wirkstoffs - enthaltend Ansammlungen von auf ein Ziel ausgerichteten Landschaftsphagenproteinen
CA2638913A1 (en) 2006-02-10 2007-09-07 The University Of Cincinnati Phosphatase inhibitor protein-1 as a regulator of cardiac function
AU2007234698B2 (en) 2006-04-07 2013-08-01 The Board Of Regents Of The University Of Texas System Methods and compositions related to adenoassociated virus-phage particles
CA2687208C (en) 2006-12-22 2017-02-14 Soluciones Biotecnologicas Innovacion Ltda Process and formulation for immunizing fish in aquaculture systems
EP2117304A4 (de) * 2007-02-07 2011-08-24 Gradalis Inc Verfahren und zusammensetzung zur modulation einer sialsäureproduktion und zur behandlung vererbter einschlusskörper-myopathie
CN101868180A (zh) 2007-10-09 2010-10-20 圣路易斯华盛顿州立大学 成像粒子
US9468607B2 (en) * 2007-10-09 2016-10-18 Washington University Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
AU2009206225B2 (en) 2008-01-25 2015-04-23 Multivir Inc. p53 biomarkers
US8563690B2 (en) * 2008-11-03 2013-10-22 The Board Of Trustees Of The University Of Illinois Modulation of platelet aggregation
US9409983B2 (en) 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
US9764043B2 (en) 2009-12-17 2017-09-19 Washington University Antithrombotic nanoparticle
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
CN103096874A (zh) 2010-04-15 2013-05-08 华盛顿大学 前药组合物、前药纳米粒子及其使用方法
MX349622B (es) 2010-09-08 2017-08-07 Halozyme Inc Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
CA2864394C (en) 2011-03-02 2021-10-19 Jack Roth A method of predicting a response to a tusc2 therapy
WO2013036799A2 (en) 2011-09-09 2013-03-14 Fred Hutchinson Cancer Research Center Methods and compositions involving nkg2d inhibitors and cancer
AU2013229786B2 (en) 2012-03-08 2017-06-22 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
EP3099801B1 (de) 2014-01-31 2020-03-18 Factor Bioscience Inc. Synthetische rna zur verwendung in der behandlung von epidermolysis bullosa dystrophica
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
HK1243000A1 (zh) * 2015-01-28 2018-07-06 瑞采生技有限公司 用於增强PPARγ表现及核转位之化合物及其医疗用途
CA2976376A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US10086089B2 (en) * 2015-09-18 2018-10-02 DNARx Systems and methods for nucleic acid expression in vivo
ES2892972T3 (es) 2015-11-02 2022-02-07 Univ Texas Métodos de activación de CD40 y bloqueo de punto de control inmunitario
WO2017079746A2 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
WO2017216775A2 (en) 2016-06-16 2017-12-21 The Regents Of The University Of California Identification of factor that promotes human hsc self-renewal
AU2017290805B2 (en) 2016-07-01 2023-11-16 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
JP7041136B2 (ja) 2016-10-12 2022-03-23 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Tusc2免疫療法のための方法および組成物
KR20190112263A (ko) 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
CN116392609A (zh) * 2017-03-23 2023-07-07 Dnarx公司 用于体内核酸表达的系统和方法
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
WO2020036635A2 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
WO2019209956A1 (en) 2018-04-25 2019-10-31 University Of Massachusetts Artificial exosome composition and related methods
EP3790533A1 (de) * 2018-05-08 2021-03-17 University of Florida Research Foundation, Incorporated Magnetische liposomen und zugehörige behandlungs- und abbildungsverfahren
CN108653750B (zh) * 2018-06-01 2022-04-22 成都诺恩基因科技有限公司 包裹质粒dna的阳离子脂质体复合物
CN113614535B (zh) 2018-10-31 2024-08-16 亚利桑那大学评议会 用于辐射诱导的肺损伤的生物标志物和使用方法
CA3149494A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
US20240409638A1 (en) 2021-10-07 2024-12-12 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
EP4413038A1 (de) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1-bindende affimere
CN119213021A (zh) 2022-02-10 2024-12-27 艾菲赛尔治疗株式会社 与CD40L特异性结合的Stefin A蛋白变体及其用途
IL316289A (en) 2022-04-29 2024-12-01 Purinomia Biotech Inc Methods and compositions for treating diseases and disorders driven by eosinophils
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5206027A (en) * 1990-09-13 1993-04-27 Fuji Photo Film Co., Ltd. Amphipathic compound and liposome comprising the same
EP0646178A1 (de) * 1992-06-04 1995-04-05 The Regents Of The University Of California Expression kassette mit im säugetier wirt funktionnellen regulator sequenzen

Also Published As

Publication number Publication date
US6413544B1 (en) 2002-07-02
DE69708919T2 (de) 2002-06-27
EP0955999A1 (de) 1999-11-17
JP4203835B2 (ja) 2009-01-07
CA2263705A1 (en) 1998-02-26
AU730771B2 (en) 2001-03-15
JP2000516630A (ja) 2000-12-12
DE69708919D1 (de) 2002-01-17
EP0955999B1 (de) 2001-12-05
AU4050297A (en) 1998-03-06
US20020028219A1 (en) 2002-03-07
CA2263705C (en) 2007-12-04
WO1998007408A1 (en) 1998-02-26

Similar Documents

Publication Publication Date Title
DE69708919D1 (de) Neue liposomkomplexe mit erhöhter systemischer verabreichung
Trubetskoy et al. Cationic liposomes enhance targeted delivery and expression of exogenous DNA mediated by N-terminal modified poly (L-lysine)-antibody conjugate in mouse lung endothelial cells
Kawakami et al. Asialoglycoprotein receptor-mediated gene transfer using novel galactosylated cationic liposomes
DE69906977D1 (de) In liposomen verkapselte nukleinsäurekomplexe
EP0759694A4 (de) Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen
ATE362991T1 (de) Kondensierte plasmid-liposome komplex zur transfektion
CA2196780A1 (en) A liposomal delivery system comprising cationic lipopolyamines and neutral lipids for delivery of biologically active agents
PT883602E (pt) Compostos lipidicos e sua utilizacao por exemplo em lipossomas
DE69730218D1 (de) Fusogene liposomen
FI963103A0 (fi) Ei-virusvektori
NO993258L (no) Peptid-lipidkonjugater, liposomer og liposomal legemiddelavlevering
WO1997011682A3 (en) Emulsion and micellar formulations for the delivery of biologically active substances to cells
ATE322255T1 (de) Polyamid-oligomere
CA2219119A1 (en) Nucleic acid ligand complexes
DE69830249D1 (de) Zielgerichtete liposomen zur verabreichung von genen
ATE419833T1 (de) Modulares zielgerichtetes liposomales verabreichungssytem
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
Chiou et al. In vivo gene therapy via receptor-mediated DNA delivery
WO1999065461A3 (en) Cationic amphiphile micellar complexes
ATE359764T1 (de) Durch liposome vermittelte dna verabreichung
CO5280052A1 (es) Virosomas cationicos dosper
MX9708111A (es) Lipidos cationicos para terapia genica.
TR199701225A2 (xx) Gen terapisi için katyonik lipidler.
CA2051439A1 (en) Liposomal targeting of ischemic tissue

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties